Cytori and Lorem Announce China Approval of Regenerative Medicine Device
April 06, 2015 at 05:38 AM EDT
Cytori Therapeutics of San Diego, together with its China-Asia licensee, Lorem Vascular, received CFDA regulatory clearance to market the Cytori Celution® System, a device that processes stem cells from adipose tissue. The companies did not specify an indication for the device, though it has been in trials elsewhere as a treatment for heart failure, scleroderma and osteoarthritis along with aesthetic uses. In 2013, Lorem signed a $531 million, 30-year deal to in-license rights for the system in China, Hong Kong, Malaysia, Singapore and Australia. More details.... Stock Symbol: (NSDQ: CYTX) Share this with colleagues: // //